Mark Lackner Sells 4,411 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) insider Mark Lackner sold 4,411 shares of Zentalis Pharmaceuticals stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.12, for a total transaction of $13,762.32. Following the completion of the transaction, the insider now directly owns 191,317 shares of the company’s stock, valued at $596,909.04. This trade represents a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded up $0.24 during trading hours on Friday, hitting $3.24. 1,591,780 shares of the company’s stock traded hands, compared to its average volume of 1,308,390. The stock’s fifty day moving average price is $3.33 and its two-hundred day moving average price is $3.54. The firm has a market cap of $230.90 million, a P/E ratio of -1.30 and a beta of 1.84. Zentalis Pharmaceuticals, Inc. has a twelve month low of $2.66 and a twelve month high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, equities research analysts predict that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of institutional investors have recently modified their holdings of the stock. Erste Asset Management GmbH purchased a new stake in shares of Zentalis Pharmaceuticals during the third quarter worth $37,000. Paloma Partners Management Co acquired a new position in shares of Zentalis Pharmaceuticals during the 3rd quarter valued at about $37,000. Aigen Investment Management LP bought a new position in shares of Zentalis Pharmaceuticals in the third quarter valued at approximately $41,000. Capstone Investment Advisors LLC bought a new stake in Zentalis Pharmaceuticals during the third quarter valued at about $48,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in shares of Zentalis Pharmaceuticals by 63.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 13,676 shares of the company’s stock worth $50,000 after buying an additional 5,333 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Oppenheimer reiterated an “outperform” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Finally, Guggenheim dropped their price target on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Five investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $10.00.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.